Oral Micronized Progesterone and Cognitive Function: What the Evidence Actually Shows

What the label says about the brain

The Prometrium label states that the drug 'may cause transient dizziness and drowsiness and should be used with caution when driving a motor vehicle or operating machinery,' and the labeled schedule is a single daily dose at bedtime [2]. During initial therapy, the label records that a few women had extreme dizziness or drowsiness, blurred vision, slurred speech, difficulty walking, loss of consciousness, vertigo, confusion, disorientation, feeling drunk, and shortness of breath [2][3].

Postmarketing reports listed in the label include sedation, depressed consciousness, disorientation, dysarthria, syncope and transient ischemic attack. These come from voluntary reports of uncertain size, so their frequency cannot be estimated [3].

The label's adverse reaction table gives rates for an estrogen-plus-progesterone arm, not for progesterone alone. In the 3-year table, cyclic Prometrium 200 mg with conjugated estrogens 0.625 mg (n=178) is compared with placebo (n=174): dizziness 15% versus 9% and depression 19% versus 12% [3]. Both figures come from women who also took estrogen, so they cannot be assigned to progesterone alone [3]. Maximum serum concentration is reached within 3 hours of an oral dose [3].

The dementia boxed warning was removed in 2026

On February 12, 2026, FDA approved labeling changes to six menopausal hormone therapy products, removing risk statements about cardiovascular disease, breast cancer and probable dementia from the boxed warning [5]. Prometrium is listed among the products whose prescribing information was updated, as the progestogen-alone product [6], and the current label, Revision 02/2026, has no boxed warning [3].

The WHI estrogen-plus-progestin data remain in the Warnings and Clinical Studies sections of the label [3].

PEPI: a randomized trial that included oral micronized progesterone

PEPI was a 3-year, multicenter, randomized, double-blind, placebo-controlled trial in 875 healthy postmenopausal women aged 45 to 64 [7]. Women were randomly assigned in equal numbers to placebo, conjugated equine estrogen 0.625 mg/day, conjugated equine estrogen plus cyclic medroxyprogesterone acetate 10 mg/day for 12 days a month, conjugated equine estrogen plus continuous medroxyprogesterone acetate 2.5 mg/day, or conjugated equine estrogen plus cyclic micronized progesterone 200 mg/day for 12 days a month [7]. The placebo group took placebo pills and no hormones, and the estrogen was conjugated equine estrogen, not estradiol [7].

PEPI's four primary endpoints were HDL cholesterol, systolic blood pressure, serum insulin and fibrinogen [7]. Its information on cognition comes from a self-reported symptom checklist collected at 1 and 3 years in the same 875 women: anxiety, cognitive and affective symptoms did not differ by treatment assignment [1].

KEEPS-Cog: cognition measured directly, but not with progesterone alone

KEEPS-Cog was a randomized study that measured cognitive test performance in recently menopausal women taking oral micronized progesterone. Of 727 women enrolled in KEEPS, 693 took part in the cognitive and affective substudy [8]. They were randomized to 0.45 mg/day oral conjugated equine estrogen plus 200 mg/day micronized progesterone for the first 12 days of each month (n=220), 50 mcg/day transdermal estradiol plus the same micronized progesterone schedule (n=211), or placebo pills and patches (n=262), for up to 4 years [8]. Mean age was 52.6 years and women were on average 1.4 years past their last menstrual period [8].

The cognitive outcomes were the Modified Mini-Mental State examination and four cognitive factors (verbal learning and memory, auditory attention and working memory, visual attention and executive function, and speeded language and mental flexibility), plus the Profile of Mood States [8]. Both active arms included estrogen, so the comparison is estrogen plus progesterone versus placebo, not progesterone alone versus placebo [8].

A single-dose study of mood and cognition

One placebo-controlled study assessed mood, cognition and motor performance after a single 1,200 mg oral dose of micronized progesterone [9]. It gave the dose to 18 healthy women aged 18 to 25 and compared plasma levels of the drug's metabolites with mood, cognition and motor performance [9]. Progesterone is reduced to allopregnanolone and pregnanolone, which have been reported to have anxiolytic, hypnotic and anesthetic actions in animals and/or humans [9].

Plasma allopregnanolone correlated with measures of fatigue, confusion and immediate recall [9]. Significant changes in fatigue, delayed verbal recall and symbol copying occurred in the women who reached high metabolite levels (at least 95.55 nmol/L), while women with lower levels reported no negative effects [9]. The dose was six times the labeled 200 mg [2][9], and the participants were young women rather than menopausal patients.

The dementia data behind the old warning come from a different progestin

WHIMS enrolled 4,532 women aged 65 or older from the WHI estrogen-plus-progestin trial, free of probable dementia, randomized to conjugated equine estrogen 0.625 mg plus medroxyprogesterone acetate 2.5 mg (n=2,229) or placebo (n=2,303) [4]. Over a mean of about 4 years, 40 women in the hormone arm and 21 in the placebo arm were diagnosed with probable dementia, a hazard ratio of 2.05 (95% CI 1.21 to 3.48; 45 versus 22 per 10,000 person-years; P=.01), or about 23 extra cases per 10,000 women per year [4]. Mild cognitive impairment did not differ (hazard ratio 1.07; 95% CI 0.74 to 1.55) [4].

The progestin in that trial was medroxyprogesterone acetate, not micronized progesterone [4].

Progesterone for brain injury: two large trials that did not work

ProTECT III randomized 882 of a planned 1,140 patients with acute traumatic brain injury to intravenous progesterone or placebo, started within 4 hours of injury and given for 96 hours; there was no significant difference in favorable outcome at 6 months (relative benefit 0.95; 95% CI 0.85 to 1.06; P=0.35), and phlebitis or thrombophlebitis was more frequent with progesterone (relative risk 3.03; 95% CI 1.96 to 4.66) [10].

SyNAPSe randomized 1,195 patients aged 16 to 70 with severe traumatic brain injury to progesterone or placebo starting within 8 hours and continuing for 120 hours; there was no treatment effect (odds ratio 0.96; 95% CI 0.77 to 1.18), and a favorable outcome occurred in 50.4% with progesterone versus 50.5% with placebo [11]. Both used intravenous progesterone in acute injury, not oral capsules in menopausal women.

Practical points from the label

• The label gives 200 mg at bedtime, for 12 days sequentially per 28-day cycle, for a postmenopausal woman with a uterus receiving daily conjugated estrogens tablets, and 400 mg at bedtime for 10 days for secondary amenorrhea [2].
• The label says that people who have difficulty swallowing should take the capsule with a glass of water while standing [2][3].
• Food increased bioavailability relative to fasting at the 200 mg dose [3].
• The capsules contain peanut oil and are contraindicated in peanut allergy [2].
• Other labeled contraindications: abnormal genital bleeding of unknown cause; known, suspected or past breast cancer; active or past deep vein thrombosis or pulmonary embolism; active or past arterial thromboembolic disease such as stroke or myocardial infarction; known liver dysfunction or disease [2].
• Progesterone may cause some fluid retention; women with cardiac or renal dysfunction warrant careful observation [2].
• Pharmacokinetics have not been studied in hepatic or renal impairment [3].